All In MedTech

FDA Clearance Tracker · P950014-S026

UROLOGIX PROSTATRON SYSTEM

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 16, 2008 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 16, 2008

Approved

Time to decision

124 days

Received Mar 14, 2008. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P950014-S026
Device name
UROLOGIX PROSTATRON SYSTEM
Applicant location
Plymouth, MN
Received
Mar 14, 2008
Decided
Jul 16, 2008
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P950014

Device type

Device class
Class III

Every decision under product code MEQ

FDA's approval statement

As written in FDA's record.

APPROVAL FOR DESIGN MODIFICATIONS WHICH INCLUDE A NEW CATHETER TIP MATERIAL, RED MARK ADHESIVE, BONDING ADHESIVES, INJECTION MOLD FOR MANUFACTURING THE CATHETER TIP, AND A NEW STERILE BALLOON INFLATION STOPCOCK. THE PRODUCTION OF THE PROSTAPROBE TYPE II, SILICONE, BLUE TREATMENT CATHETER (PART NUMBER 410053-004) WILL BE MANUFACTURED AT MEDTECH COSTA RICA, SA, COSTA RICA, CENTRAL AMERICA.

Source documents

Other decisions for Urologix, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.